본문으로 건너뛰기
← 뒤로

Radiosensitization by Docetaxel Prodrug-Loaded Lipid Nanoparticles in Pancreatic Cancer Xenografts.

Nanomaterials (Basel, Switzerland) 2025 Vol.15(19)

Alhussan A, Jackson N, Dos Santos N, Chen S, Tam YYC, Chithrani DB

📝 환자 설명용 한 줄

Cancer treatments are limited by poor tumor specificity and toxicity.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Alhussan A, Jackson N, et al. (2025). Radiosensitization by Docetaxel Prodrug-Loaded Lipid Nanoparticles in Pancreatic Cancer Xenografts.. Nanomaterials (Basel, Switzerland), 15(19). https://doi.org/10.3390/nano15191521
MLA Alhussan A, et al.. "Radiosensitization by Docetaxel Prodrug-Loaded Lipid Nanoparticles in Pancreatic Cancer Xenografts.." Nanomaterials (Basel, Switzerland), vol. 15, no. 19, 2025.
PMID 41090865

Abstract

Cancer treatments are limited by poor tumor specificity and toxicity. We tested a radiosensitizing approach using PEG/RGD-functionalized gold nanoparticles (GNPs), a lipid-nanoparticle-encapsulated docetaxel prodrug (LNP), and external-beam radiotherapy (RT). In MIA PaCa-2 xenografts, intravenous GNPs (2 mg/kg) and LNP (6 mg/kg) were given before 5 Gy RT. Both LNP + RT and GNPs + LNP + RT reduced tumor volume by ~40% and significantly prolonged survival versus RT alone ( < 0.001). Adding GNPs did not enhance efficacy, indicating LNP was the main driver under this regimen. These results demonstrate nanocarrier-enabled radiosensitization in vivo and support further studies toward clinical translation.

같은 제1저자의 인용 많은 논문 (1)